Bookmark and Share
BioAssay: AID 624205

Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (3)

This functional assay was developed for detection of compounds inhibiting Vero E6 cells viability as a secondary screen to the PFM18AAP screen. ..more
_
   
 Tested Compounds
 Tested Compounds
All(45)
 
 
Active(31)
 
 
Inactive(11)
 
 
Inconclusive(3)
 
 
 Tested Substances
 Tested Substances
All(46)
 
 
Active(32)
 
 
Inactive(11)
 
 
Inconclusive(3)
 
 
 Related BioAssays
 Related BioAssays
AID: 624205
Data Source: Southern Research Specialized Biocontainment Screening Center (PfM18_Tox_03)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2012-05-25
Hold-until Date: 2013-04-19
Modify Date: 2013-04-19

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 31
Related Experiments
Show more
AIDNameTypeComment
1855Summary of probe development efforts to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP)Summarydepositor-specified cross reference: Summary AID
588678QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP)Confirmatorydepositor-specified cross reference: PFM18AAP Confirmatory Assay
588679Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP)Confirmatorydepositor-specified cross reference: Counter Screen PFM17LAP Confirmatory Assay
588680Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP)Confirmatorydepositor-specified cross reference: Counter Screen PFM1AAP Confirmatory Assay
588696Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP)Confirmatorydepositor-specified cross reference: Counter Screen Hum1AAP Confirmatory Assay
588714Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP)Confirmatorydepositor-specified cross reference: Cytotox
602219Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP) (2)Confirmatorydepositor-specified cross reference: Counter Screen PFM1AAP Confirmatory Assay
602220Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (2)Confirmatorydepositor-specified cross reference: Counter Screen PFM17LAP Confirmatory Assay
602221Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP) (2)Confirmatorydepositor-specified cross reference: Counter Screen Hum1AAP Confirmatory Assay
602222QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (1)Confirmatorydepositor-specified cross reference: PFM18AAP Confirmatory Assay
602225Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (2)Confirmatorydepositor-specified cross reference: Cytotox
720736Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2Otherdepositor-specified cross reference
743024Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based dose response assay to identify compounds that inhibit P. falciparum growth in RBCs, Set 2.Confirmatorydepositor-specified cross reference
1822QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).Screeningsame project related to Summary assay
1906QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).Screeningsame project related to Summary assay
2170QFRET-based biochemical high throughput confirmation assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).Screeningsame project related to Summary assay
2178QFRET-based counterscreen for inhibitors of PFM18AAP: biochemical high throughput confirmation assay for inhibitors of the Cathepsin L proteinase (CTSL1).Screeningsame project related to Summary assay
2195QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).Confirmatorysame project related to Summary assay
2196QFRET-based counterscreen for inhibitors of PFM18AAP: biochemical high throughput dose response assay for inhibitors of the Cathepsin L proteinase (CTSL1).Confirmatorysame project related to Summary assay
489011Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based dose response assay to identify compounds that inhibit P. falciparum growth in RBCsConfirmatorysame project related to Summary assay
489015Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCsOthersame project related to Summary assay
492974Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Alanyl Aminopeptidase (PfM18AAP): fluorescence-based biochemical assay to identify inhibitors of rPfM18AAPScreeningsame project related to Summary assay
492975Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Alanyl Aminopeptidase (PfM18AAP): fluorescence-based biochemical assay to identify inhibitors of malaria cell lysateScreeningsame project related to Summary assay
624174Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP) (3)Confirmatorysame project related to Summary assay
624175Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (3)Confirmatorysame project related to Summary assay
624176Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP) (3)Confirmatorysame project related to Summary assay
624177QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (2)Confirmatorysame project related to Summary assay
Description:
Southern Research Specialized Biocontainment Screening Center (SRSBSC)
Assay Provider: Donald Gardiner
Award: 1 R03 MH082342-01A1
This functional assay was developed for detection of compounds inhibiting Vero E6 cells viability as a secondary screen to the PFM18AAP screen.

In this assay, we treated Vero E6 cells with compounds selected as hits in the PFM18AAP assay for 72 hours over a 10 point 2-fold dilution series, ranging from 0.19uM to 100 uM. Following 72 hours of treatment, relative viable cell number was determined using Cell Titer Glo from Promega. Each plate contained 64 replicates of vehicle treated cells which served as negative controls.
Protocol
Cell Culture: Vero E6 cells were subcultured every 7 days in E-MEM with 10% fetal bovine serum and 2 mM glutamine (complete growth medium), incubated at 37 degrees C in 5% carbon dioxide, and maintained for no more than 20 passages.
Compound Dosing/Plating: Carrier control / compounds were diluted in complete growth medium to prepare a 6X concentrated dosing solution which was dispensed into 384-well black clear-bottom tissue culture treated plates (5 uL volume).
Cell Plating: Twenty uL of complete growth medium containing 3000 cells were dispensed per well. Plates were incubated at 37 C, 5% CO2 for 72h prior to endpoint detection.
Endpoint/Detection: At the end of the treatment period, assay plates were removed from the incubator and equilibrated to room temperature for 10 min. Twenty-five uL of Cell Titer Glo reagent was added and plates were incubated for an additional 10 min in the dark. At the end of the incubation, assay plates were analyzed using a PerkinElmer Envision microplate reader in luminescence mode with an integration time of 0.1 s.
Data Analysis: Sixty-four control wells containing cells treated with DMSO vehicle and were included on each assay plate. Compound data was normalized and reported as % viability which was calculated using the following formula: % viability = 100*(Cmpd Lum-Med background)/(Med Cell Ctrl - Med background). The normalized % viability was plotted against the tested concentrations. The CC50 values were calculated using XLfit formula 205, a 4 parameter Levenburg-Marquardt algorithm with maximum and minimum limits set at 100 and 0, respectively and allowing extrapolation to identify weakly active compounds.
Comment
Outcome: Compounds that showed <80% cell viability for at least one concentration were defined as "Active" (toxic). If the % viability at all doses was <80%, the compound was defined as "Inactive" (non-toxic). Instances where replicate data sets conflicted on this criteria are listed as "Inconclusive".
The following tiered system has been implemented at Southern Research Institute for use with the PubChem Score: Compounds in the primary screen are scored on a scale of 0-40 based on % activity; a score of 40 corresponds to 100% activity. In the confirmatory dose response screen of primary screen hits, active compounds are scored on a scale of 41-80 based on CC50 result while compounds where activity was not confirmed are given the score 0. Confirmatory dose response and secondary screens of purified and/or resynthesized compounds, indicating the highest degree of confidence) are scored on a scale of 81-100 based on CC50 result. Inactive compounds are given the score 0.
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
BAO: assay design: viability reporter:atp content
BAO: assay format: cell-based format
BAO: bioassay specification: assay biosafety level: BSL2
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: none
BAO: bioassay specification: assay readout content: content readout type: protein target: enzyme: transferase: kinase
BAO: bioassay specification: assay stage: Secondary:counterscreening
BAO: detection technology: luminescence: chemiluminescence
BAO: meta target detail: binding reporter specification: interaction: protein:small molecule
BAO: meta target: molecular target: cell death
BAO: version: 1.4b1090
From PubChem:
Assay Format: Cell-based
Assay Type: Toxicity
Assay Cell Type: VERO 76
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Avg CC50 ModifierString
2Avg CC50*FloatμM
3CC50 Modifier Rep 1String
4CC50 Rep 1FloatμM
5CC50 Modifier Rep 2String
6CC50 Rep 2FloatμM
7CC50 Modifier Rep 3String
8CC50 Rep 3FloatμM
9StDev CC50 Modifier Rep 1String
10StDev CC50 Rep 1Float
11CC50 Hill Slope Rep 1Float
12CC50 NormChi2 Rep 1Float
13StDev CC50 Modifier Rep 2String
14StDev CC50 Rep 2Float
15CC50 Hill Slope Rep 2Float
16CC50 NormChi2 Rep 2Float
17StDev CC50 Rep 3Float
18CC50 Hill Slope Rep 3Float
19CC50 NormChi2 Rep 3Float
20% Viability at 50 uM Rep 1 (50μM**)Float%
21% Viability at 25 uM Rep 1 (25μM**)Float%
22% Viability at 12.5 uM Rep 1 (12.5μM**)Float%
23% Viability at 6.25 uM Rep 1 (6.25μM**)Float%
24% Viability at 3.13 uM Rep 1 (3.13μM**)Float%
25% Viability at 1.56 uM Rep 1 (1.56μM**)Float%
26% Viability at 0.78 uM Rep 1 (0.78μM**)Float%
27% Viability at 0.39 uM Rep 1 (0.39μM**)Float%
28% Viability at 0.2 uM Rep 1 (0.2μM**)Float%
29% Viability at 50 uM Rep 2 (50μM**)Float%
30% Viability at 25 uM Rep 2 (25μM**)Float%
31% Viability at 12.5 uM Rep 2 (12.5μM**)Float%
32% Viability at 6.25 uM Rep 2 (6.25μM**)Float%
33% Viability at 3.13 uM Rep 2 (3.13μM**)Float%
34% Viability at 1.56 uM Rep 2 (1.56μM**)Float%
35% Viability at 0.78 uM Rep 2 (0.78μM**)Float%
36% Viability at 0.39 uM Rep 2 (0.39μM**)Float%
37% Viability at 0.2 uM Rep 2 (0.2μM**)Float%
38% Viability at 50 uM Rep 3 (50μM**)Float%
39% Viability at 25 uM Rep 3 (25μM**)Float%
40% Viability at 12.5 uM Rep 3 (12.5μM**)Float%
41% Viability at 6.25 uM Rep 3 (6.25μM**)Float%
42% Viability at 3.13 uM Rep 3 (3.13μM**)Float%
43% Viability at 1.56 uM Rep 3 (1.56μM**)Float%
44% Viability at 0.78 uM Rep 3 (0.78μM**)Float%
45% Viability at 0.39 uM Rep 3 (0.39μM**)Float%
46% Viability at 0.2 uM Rep 3 (0.2μM**)Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R03 MH084103-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: